If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Look for the launch of Alyftrek to boost Vertex's sales in the coming quarters. Vertex is also picking up momentum with its ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...